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Abstract 
The animal health industry is a growing industry. Owners of pets and other animals want 
to ensure their animals are healthy. To do this, the animal health industry markets a variety of 
products from pharmaceutical products, such as antibiotics, to biological products, such as 
vaccines. These products are developed and marketed after the company provides regulators the 
necessary information as guided by a set of regulations. Pharmaceutical products follow Title 21 
of the Code of Federal Regulations, while biological products follow Title 9 of the Code of 
Federal Regulations. During the product development process as well as after marketing, 
regardless of the regulations to follow, each product must go through testing for efficacy, safety, 
potency, and stability.  The regulatory guidelines provide direction to companies on expectations 
of the testing requirements for each type of product. Different analytical techniques are used to 
provide the necessary data in support of product development. Discussed in this report, two 
analytical techniques are well known in the industry, and one is quickly becoming a technique of 
great value. Mass spectrometry, coupled with liquid chromatography, is an industry standard for 
testing product potency and purity as well as pharmacokinetics. The enzyme-linked 
immunosorbent assay (ELISA) is also used to measure potency of products as well as product 
stability. The newest technique is flow cytometry that characterizes cells within a suspension, 
most often with the use of cellular biomarkers as targets.  By understanding the application of 
each technique as well as how it relates to regulatory requirements, the industry can provide 
assurances to regulators that their products are safe and efficacious for the treatment and/or 
prevention of animal diseases. This report outlines the history, theory, and use of three different 
analytical techniques currently used for pharmaceutical and biological products in animal health.
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Chapter 1 - Introduction 
Animals provide a few roles for humans. They are companions and a source of food. 
Because of these roles, the animal health industry is growing today. Taking care of the animals is 
up to the people who own them. Animal owners rely on pharmaceutical and biological 
companies to supply pharmaceutical products, such as antibiotics, and biological products, such 
as vaccines, to support the health and welfare of their animals. These products are developed and 
marketed as efficacious and safe products for the animals. This is accomplished by two United 
States (U.S.) regulatory entities. These regulatory bodies guide animal health companies through 
the product development process and are Center of Veterinary Medicine (CVM) of the Food and 
Drug Administration (FDA) and Center for Veterinary Biologics (CVB) of the United States 
Department of Agriculture (USDA). There are many more divisions within the FDA and USDA, 
but these two major divisions are important for animal health and the subsequent testing of the 
pharmaceutical and biological products used to treat animals.  
The growing industry can be seen by the sale of their products. As of 2015, the top 10 
animal health corporations are Zoetis, Merck Animal Health (Merck & Co.), Elanco (Eli Lilly), 
Merial (Sanofi), Bayer Animal Health (Bayer), Boehringer Ingelheim Vetmedica (Boehringer 
Ingelheim), IDEXX Laboratories, Ceva Sante Animale (Ceva), Virbac S.A., and Vetoquinol S.A. 
(Weintraub 2015). These companies produce products ranging from biological agents (like 
vaccines) to parasiticides (like flea and tick products). They also include such products as 
antibiotics, anthelmintics (de-wormers), and antifungals. Several of these companies are global 
companies, selling their products worldwide. In order to sell these products, each product must 
go through many stages of testing to show safety and efficacy for each animal species. Animal 
targets for these products range from bovine (cattle) and swine (pigs) to poultry (chickens and 
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turkeys), and also include dogs and cats among many others.  Annual sales from animal health 
products for five of the top companies in 2015 are shown in Table 1:1. 
Table 1:1 Animal Health Companies 2015 Reported Revenue 
Company
1 
2015 Year end Revenue (billions) 
Zoetis  $ 4.8 
Merck Animal Health (Merck & Co.) $ 3.324 
Elanco (an Eli Lilly company) $ 3.181 
Bayer Animal Health (Bayer) $ 1.60 (€ 1.49) 
Merial (purchased by Boehringer Ingelheim) $ 1.43 (€ 1.331) 
1
Dollars obtained from company annual reports available on their respective websites. 
Animal health product development can take 5 to 15 years to get to marketing. The 
amount of money needed is several millions of dollars (Yarbrough 2016). This makes it 
important to know the content of each vial or capsule of product administered to the animal 
because the cost of a recall of product or re-development of a product could be substantial. The 
regulatory process includes testing at different stages of the process. Initial amounts of the 
organism (for biological products) or Active Pharmaceutical Ingredient (API) (for 
pharmaceutical products) are determined per regulations. Testing of the vial of vaccine or 
capsule of pharmaceutical product after manufacturing is also required to meet regulations. 
These regulatory requirements help ensure the products are administered with equivalent 
amounts of the active ingredient from batch to batch and provide the same efficacious quality 
each and every time. The testing is done through approved or validated procedures with quality 
control performed routinely. Because efficacy and safety are of concern for pharmaceutical and 
biological products, study designs and analytical techniques are needed to ensure that the final 
manufactured product is within acceptable limits. The purity and/or potency testing of the 
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different types of products uses different techniques during the development process of a 
pharmaceutical and biological product, and includes, but are not limited to, liquid 
chromatography, enzyme-linked immunosorbent assay (ELISA), and flow cytometry.  Generally, 
liquid chromatography is used in the drug development process to test 1) the purity of the active 
pharmaceutical ingredient, 2) concentration of the analyte versus the administration time profile 
to determine the pharmacokinetics profile, and 3) as one of the stability assays for the reference 
material used in vaccine potency assays. ELISA is generally used to test 1) the potency of the 
vaccine product, 2) the reference material used in the potency assays, and 3) pharmacokinetic 
analysis. Flow cytometry assays are used for 1) biomarker analysis in which a sample is analyzed 
for the presence of disease, infection or environmental exposure, 2) the properties of cells, such 
as looking for antigen specific T cell response, and 3) other types of cellular analyses, such as 
cell viability. 
The purpose of this report was to highlight three analytical techniques used to support 
regulatory requirements for marketing of pharmaceutical and biological products. This report is 
limited to these particular techniques because of their current (liquid chromatography, ELISA) 
and potential (flow cytometry) use within the industry.  There are other analytical techniques 
available for testing; however, these particular assays are recognized standards, and 
governmental regulatory agencies accept the data from these assays in support of the marketed 
products. Some practical uses and examples of these techniques are discussed at the end of the 
report.  To understand why the regulators accept the data from these analytical assays, this report 
will also review the evolution of the regulatory requirements for testing animal health products 
and explain how these testing techniques seek to fulfill these regulations. 
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Chapter 2 - Regulations 
The United States (U.S.) governmental body puts laws in place to help keep the general 
public safe and ensure their rights as citizens of the U.S. are upheld. Some laws are intended to 
provide guidance to the industry on the expectations of the regulators for marketing of animal 
health products, such as pharmaceuticals or biologics. The U.S. government issues laws. These 
laws are codified; that is, laws are written based on their subject matter.  The United States Code 
(U.S.C.) features the laws passed by the government. The Code of Federal Regulations (CFR) is 
developed in response to the United States Code (U.S.C.). The CFR is the regulation used to 
enforce the law. Each new law is recorded in the U.S.C. book, and subsequently, the new 
regulation issued is recorded in the CFR book. The law is not enforced without a regulation to 
govern it.  
 United States Code (U.S.C.) 
 History 
 The United States issued Statutes, a collection of laws, to provide some guidance to the 
public. In 1873, the revised Statutes were codified, gathered and written as collections of subject 
matter. By June 30, 1926, President Calvin Coolidge signed the U.S.C. as enforced. This date 
was when some of the laws had improved organization and became enforceable. The laws were 
considered positive laws, or enacted laws (McKinney 2004). 
 Code of Federal Regulations (CFR) 
 History 
The Code of Federal Regulations is the rules used to enforce the U.S.C. The Federal 
Register Act, passed by Congress in 1935 gave the Archivist of the United States the ability to 
establish a division within the National Archives, which would publish a daily publication of the 
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Federal Register. This register made public all regulations as well as Presidential proclamations 
and executive orders. It was amended in 1937 to provide a codification of all regulations were 
made public every five years. By 1938, the first edition of the CFR was published which 
included all finalized regulations that were published since 1936 or before which were still in 
effect. Supplements were published yearly except during war times. In 1946, the Administrative 
Procedures Act was set to make any notice of proposed rules available and publicized. The 
second edition of the CFR was published in 1949. Starting in 1963, yearly publications are 
available. Yearly revisions to the CFR were determined were unmanageable. The CFR was 
divided into 4 groups, and the review process was staggered between the 4 groups. By the 
1960’s, each finalized rule was accompanied by brief explanations about the rule. In 1973, these 
explanations were part of the preamble to the rule. Since 1977, the requirement for the preambles 
included headings and related material.  When a rule became effective, the comments to 
proposed rules, along with answers, were summarized (McKinney 2002).  
 Rulemaking Process 
 Regulations the pharmaceutical and biological companies follow go through a process to 
become effective. An “Advance Notice of Proposed Rulemaking” may be published in the 
Federal Register in the preliminary stages. The President of the U.S., as the head of the 
Executive Branch, can review a proposed rule with the assistance of the Office of Information 
and Regulatory Affairs (OIRA). Each rule goes through the steps outlined in Table 2:1. In step 1, 
the notice of proposed rulemaking (NPRM) is used to announce and explain the agency’s plan 
for addressing issues or to reach a goal. Each proposed rule includes a preamble, which includes 
a summary of the problems or actions being considered. Dates for comment are listed. Table 2:2 
summarizes the date period for comment. Step 2 of the process is to request comments from the 
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public. Step 3 gives advice on whether the rule is to continue in the comment process or proceed 
to finalization. Finally, step 4 is when the final rule is published under Title 21 of the CFR. Rules 
generally become effective within 30 days of publication in the Federal Register, but this 
timeline may be extended for complex or significant rules  (Office of Federal Register 2017). 
Table 2:1 Rulemaking Process 
Step # Comment 
1 Propose a new rule 
2 Ask for Public comments 
3 Regulators consider/synthesize/address public comments. 
a. If further action to the proposed rule is needed, issue a new 
proposed/revised rule 
 
b. If no further action to the proposed rule is needed, issue the final rule 
4 Publish Final Rule in the Federal Register and include: 
a. Regulatory Requirements 
b. Impact of Requirements on industry and public 
c. Respond to comments on the proposed rule 
 
Table 2:2 Comment Period for Proposed Rules 
Period Reason 
Up to 30 to 60 days General timeframe for taking comments 
Up to 180 days Timeframe for complex rules under consideration 
Extension If the public does not feel there is enough time to give proper comments 
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 Animal Health Pharmaceutical Products 
The Center for Veterinary Medicine (CVM) of the Food and Drug Administration (FDA) 
follows Title 21 of Code of Federal Regulations and associated guidance documents when 
inspecting any New Animal Drug Application and enforcing the U.S. laws. They are committed 
to “Protecting Human and Animal Health.” (Center for Veterinary Medicine)  Title 21 of the 
CFR is the regulation based on Title 21 U.S.C. chapter 9 sections 321 – 399f, of the Federal 
Food, Drug, and Cosmetic Act.  
The Food and Drugs Act of 1906 was enacted to ban any movement of adulterated or 
misbranded food or drugs through interstate commerce. It also made any production of 
adulterated or misbranded foods or drugs unlawful within any territory of the U.S. and District of 
Columbia. The law defines drugs as all medicines or preparations recognized by the United 
States Pharmacopeia or National Formulary and are used internally or externally as well as any 
substance or mixture of substances intended for a cure, mitigation, or prevention of disease in 
both humans and animals. Adulteration is the process of selling of a product in which the official 
or recognized name is used without meeting the standards for strength, quality, or purity. If the 
label was clear with this information, the product was not considered adulterated so long as the 
company was producing a quality product according to the standards of the company. 
Misbranding is the falsification of the drugs identity on the label by using an imitation or false 
name. If the labels failed to show the quantities of the components or a lack of components, it 
was also considered misbranded (Congressional Research Service 1989). 
In 1912, the Sherley Amendment was passed to prohibit false or fraudulent therapeutic 
claims on a label. Later, in 1938, the Food and Drugs Act was revised. This became the Federal 
Food, Drug, and Cosmetic Act of 1938. A deadly incident with “Elixir of Sulfanilamide” caused 
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death because the chemists manufacturing the drug failed to test for safety; they only tested for 
flavor, appearance, and fragrance. The sulfanilamide was dissolved in diethylene glycol, a deadly 
poison. Deemed the Copeland Act, the revision now encompasses cosmetics. The act required 
any new product have proof of testing. All new drugs then required submission of full reports of 
investigations to establish safety prior to marketing of the product, but the requirements for 
proving efficacy were not yet established (Congressional Research Service 1989). 
By 1962, the Drug Amendments were added enhance regulatory authority and required 
products were manufactured in a licensed facility. This included batch certification where 
batches of drug product were required to show results of tests for efficacy and safety. The Drug 
Amendments were enacted in response to the “thalidomide disaster.” Thalidomide was a drug 
product used as a sedative as well as to help pregnant women with morning or all day illness. 
Unfortunately, it caused birth defects in children when used while a woman was pregnant. This 
drug was not yet approved in the U.S. when the disaster happened; it was distributed to doctors 
for experimental use. The government now requires approval of a drug prior to marketing and 
distribution (Congressional Research Service 1989). 
In 1968, provisions to the Federal Food, Drug, and Cosmetic Act were made to include 
all regulations of new animal drugs. This Amendment removed the requirement to regulate new 
animal drugs by the Food, Drug, and Cosmetic Act and as a food additive, thereby reducing the 
time to get to market (Congressional Research Service 1989). 
Title 21 of the CFR is entitled “Food and Drugs.” Chapter I under Title 21 of the CFR is 
entitled “Food and Drug Administration, Department of Health and Human Services.” 
Subchapter E entitled “Animal Drugs, Feed, and Related Products.” Parts 510, 511, and 514 of 
Subchapter E guide a pharmaceutical company on how to obtain a licensed product for sale. 
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Guidance for the Industry (GFI) as well as Veterinary International Conference on 
Harmonization (VICH) guidance documents provide additional guidance for licensing of 
products and are related to parts 510, 511, and 514 of subchapter E. These guidance documents 
are not enforceable by regulators, but provide the agency’s current thinking on the topic. They 
are considered recommendations unless cited as a statutory requirement. Each GFI document 
lists the respective sections of the 21 CFR under clarification in the document. Each GFI 
document also may relate back to the 21 U.S.C. requirements. The GFI and VICH work in 
tandem with each other to help guide the company in their quest of marketing a new animal drug. 
Figure 2:1 illustrates the timeline a pharmaceutical company follows during the development 
process.  
Analytical techniques to test the products are used throughout the discovery/development 
process. In the preclinical development phase, drug products go through feasibility studies in 
which the company determines the concentration of the active ingredient necessary to induce a 
therapeutic response. Analytical assays are developed to provide a way to measure the active 
ingredient for consistency during production. Also, analytical assays are developed to test for 
concentration of the active ingredient after administration. Over the next few years, research and 
development optimize and validate the assays to ensure reproducibility for subsequent uses. The 
data is compiled and submitted to the regulatory agency, CVM, for review and approval of the 
products intended therapeutic area. Testing continues to occur throughout the product’s 
development period. Post-marketing testing for the stability of the product as it is stored in the 
warehouse, veterinary clinic, or owner’s house provides assurance the product minimizes 
degradation when stored as per label requirements and used before product expiration.  
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Figure 2:1 Timeline for Animal Health Pharmaceutical Process 
 
 Animal Health Biological Products 
The Center for Veterinary Biologics (CVB) of the United States Department of 
Agriculture (USDA) and under the Animal and Plant Health Inspection Service (APHIS) follows 
Title 9 of Code of Federal Regulations and associated veterinary services memorandums (VSM) 
when inspecting a New Biological License Application and enforcing the laws. Title 9 of the 
CFR is the regulation based on Title 21 U.S.C. chapter 5 sections 151-159, the Virus-Serum-
Toxin Act.  
The Virus-Serum-Toxin Act of 1913 was enacted to provide the government the authority 
to issue licenses and regulate products and trade relating to biologics. This act was mainly in 
response to losses from the use of unregulated of anti-hog cholera serum. In 1985, the act was 
amended because of new challenges arising over the years. These challenges stemmed from 
modernization of the agricultural sector and more complicated regulations. The amendment was 
part of the Food Security Act which provided authority to the USDA to regulate intrastate (within 
states) and interstate (across states) movement of biological products. The amendment increased 
the Secretary of Agriculture’s authority to issue regulations and enhance enforcement. The 
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amendment also recognized the need to prevent and eliminate issues in commerce as well as 
regulate commerce. In 2002, the Homeland Security Act transferred most of the major functions 
of border inspection to the Department of Homeland Security (DHS) without changing any 
provisions in the original act. DHS conducts all inspections while the USDA has jurisdiction, i.e. 
the ability to make legal decisions over the regulations and policies. The act specifies any 
activity related to the preparation, sale, barter, or exchange of any dangerous virus, serum, toxin, 
and equivalent product either shipped or delivered within the borders of the U.S. unlawful 
(Monke 2005). 
Title 9 of the CFR is entitled “Animal and Animal Products.” Chapter I of Volume 1 
under Title 9 of the CFR is entitled “Animal and Plant Health Inspection Service, Department of 
Agriculture.” Subchapter E entitled “Viruses, Serums, Toxins, and Analogous Products; 
Organisms and Vectors” Parts 101-124 guides a biological company on how to obtain a licensed 
product for sale. Veterinary Services Memorandums (VSM) numbers 800.50 to 800.301 provide 
additional guidance for licensing of products and are related to parts 101-124 of subchapter E. 
Each memorandum lists the respective sections of 9 CFR that is clarified in the document. All 
these documents help a biological company in their quest to license and market a new biological 
product. Figure 2:2 illustrates the timeline a biological company follows during the development 
process. 
During the biological development process, testing is initiated during the feasibility 
studies. The feasibility studies (pre-clinical studies) are where the company determines the 
concentration of the organism necessary to induce an immune response. Analytical assays are 
developed to provide a way to measure the viability of the organism for consistency during 
production.  This testing begins with the development stage prior to submitting the development 
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plan. Over the next few years, the assays are optimized to maximize the assays ability to 
reproduce the results with each test of product. Testing occurs every time the product is produced 
during the development stage before the product is administered to the animals. One of the 
critical reagents for the product testing is the reference material. The reference material is used in 
the analytical testing technique to compare the newly produced product for determining potency. 
The data is compiled and submitted to the regulatory agency, CVB, for review and approval of 
the product’s intended therapeutic area. Testing continues to occur throughout the product’s 
development. Post-marketing testing for the stability of the product as it is stored in the 
warehouse, veterinary clinic, farmer’s barn, or owner’s house provides assurance the product 
does minimizes potency loss when the product is stored according to the label specifications. 
 
 
Figure 2:2 Timeline for Animal Health Biologic (Vaccine) Process 
Abbreviations: 
USDA United States Department of Agriculture GMO 
 
Genetically Modified Organism 
 
PLA Product License Application 
 
DOI Duration of Immunity 
 
SIF Summary of Information Format 
 
PLS Pre-licensing Serials 
 
FST Field Safety Trial 
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 Industry Testing of Products  
Figures 2:1 and 2:2 show the timeline a company would typically follow for development 
of a pharmaceutical or biological product, respectively. Each product goes through a series of 
testing to demonstrate safety and efficacy. Prior to and during the testing of the product for 
safety and efficacy, the pharmaceutical and biological companies must develop assays for testing 
of product concentration, testing for potency and purity of the product to show consistency 
between batches of manufactured product, and testing of components that are not the compound 
of interest, such as excipients or adjuvants, within each product administered to the animal to 
produce the desired medicinal result. Assays developed are standardized within each industry. 
The guidelines, either Title 21 of the CFR or Title 9 of the CFR, state what testing is done.  The 
companies are responsible for developing and/or validating the assays. One type of assay 
companies validate is for the determination of sample concentration of pharmaceutical drug as a 
function of time to calculate toxicity, i.e. target animal safety, pharmacodynamics, and 
pharmacokinetics. Bioanalysis, a division of analytical testing to quantitatively measure drug 
products in a biological system, follows the guidelines of Good Laboratory Practices, GLPs, Title 
21 of the CFR part 58. Assays used to test pharmaceutical drug potency, purity, and residual 
components must follow Good Manufacturing Practices, GMPs, Title 21 of the CFR part 210, 
211 or 226. Assays used to test biological potency, purity, and other components of the product 
called excipients follow USDA Title 9 of the CFR. To accomplish these assays several analytical 
techniques are used and include liquid chromatography, enzyme-linked immunoassays (ELISA), 
and flow cytometry assays.  There are other assay types available, such as titration techniques, 
polymerase chain reaction (PCR) for amplification, quantitative reverse transcription PCR 
(qPCR) for testing of RNA (ribonucleic acid) in starting material, thin layer chromatography, 
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nuclear magnetic resonance spectroscopy (NMR) for testing of magnetic properties of a material, 
and more; however, liquid chromatography and ELISA are considered the standard for use 
within the industry. Flow cytometry is relatively new to the industry and is rapidly becoming a 
state of the art technique. These three assays are the focus of this report.   
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Chapter 3 - Liquid Chromatography 
 History   
Liquid chromatography is an analytical technique used to separate molecules. A Russian 
botanist Mikhail Tswett was credited with the invention of chromatography in 1903. On March 
8, 1903, Tswett gave a lecture entitled “On a New Category of Adsorption Phenomena and their 
Application to Biochemical Analysis.” at the Biological Section of the Warsaw Society of 
Natural Sciences. The lecture described his wide-ranging investigations of leaf pigments, 
specifically a technique that used adsorption to separate the leaf pigments. Tswett published a 
book on the technique after refining the process entitled Chlorophylls in the Plant and Animal 
World (Ettre 2003). Tswett’s technique utilized a glass column packed with adsorptive material, 
such as alumina or silica or even powdered sugar. Then, he added a solution of plant pigments to 
the top of the column and washed the column with an organic solvent. As the solvent flowed 
through the column, the plant pigments were washed down the column and separated into a 
series of discrete colored bands, with empty bands in between.  
Another notable person in the development of chromatography was Archer J.P. Martin. 
Martin won a Nobel Prize along with his colleague Richard Synge for their development of 
partition chromatography in 1952. Where Tswett used a column of powdered chalk to separate 
the leaf pigments from the plants, Martin investigated the use of silica gel columns to separate 
amino monocarboxylic acids. This led Martin to develop partition chromatography. (Martin 
1952). As time went on, Martin continued research using gas chromatography with a glass 
column measuring four feet long by one-fourth inch diameter. This was positioned vertically and 
filled with 200-mesh granules of thin layer of non-volatile hydrocarbon coated Celite (a 
diatomaceous earth or the remains of skeletal single cell algae). Next, Martin invented the gas 
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density balance for use as the detector. This simply made instrument used the imbalance of two 
flows of gas to measure the density difference between the gases. Both the column and detector 
were heated to 180°C. Martin utilized this for analysis of hydrolyzed fatty acids and lipids to 
methyl ethers. His success showed a reduction in time for analysis (Lovelock 2004). 
 Mass Spectrometry 
Mass spectrometry is related to liquid chromatography. Where liquid chromatography is 
used as a separation technique, mass spectrometry is the detection/quantification tool and  
defined as an instrument used to separate a component into its associated ions according to their 
charge and mass. Mass spectrometry did not start out as a detector for the separation of 
components in tandem with liquid chromatography; instead, it was initially used to demonstrate 
the existence of isotopes. By the 1940’s, the petroleum industry was using mass spectrometry to 
measure the amount of small hydrocarbons in their process streams. Then, in the 1960’s, other 
chemists understood the range of applications a mass spectrometer was useful to support. Some 
examples are the determining of the earth’s age, enriching compounds with carbon (13C) for 
tracing studies, separating two isotopes of uranium, and more  (Griffiths 2008).  
 Theory 
Chromatography is a method of separation of a chemical mixture, which is carried 
through an apparatus by a liquid or gas. Figure 3:1 shows the flow diagram of liquid 
chromatography. The components are distributed between two phases, the stationary phase (the 
system in which the components are separated) and the mobile phase. As the mobile phase, 
liquid or gas, moves through the stationary phase, the chemicals are separated by repeated 
sorption/desorption during the movement. Gas mobile phase is an inert gas where as a liquid 
mobile phase is a liquid of low viscosity. The stationary phase is usually a porous, granular 
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powder packed into a tube, and referred to as the column. Each column can withstand a certain 
amount of pressure. Each small amount of sample, usually microliters in size, is carried through 
the column by the mobile phase. Liquid chromatography is a separation technique which requires 
an external instrument to detect the molecules as they leave the column. This is accomplished by 
the use of a detector and is subsequently by computer software. In the 1990’s, electronic 
integrators and microcomputers were used to collect the data and translate electronic signals into 
what are called chromatograms (see Figure 3:2). These are a record of the concentration or 
profile of the sample components as a function of the movement of the mobile phase across the 
column. Information in the chromatograms used for quantitative or qualitative analysis is the 
retention time, peak height, peak area, and baseline noise (Poole and Poole 1991). Retention time 
is the time it takes to remove a specific analyte from the column by washing with a solvent. Peak 
height is the response height of the peak from the baseline to the center of the peak. Peak area is 
the area under the response curve. Baseline noise is the movement of the response that is 
detected from the mobile phase components and should be less height or area than the peak(s) of 
interest based on a signal to noise calculation between the peak of interest and the noise. Many 
validated assays set a criteria threshold for the baseline response in order to accurately identify 
the peak(s) of interest. 
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Figure 3:1 Chromatography Flow Diagram 
 
 
Figure 3:2 LC Chromatogram  
 
Detection 
Different instruments can accomplish detection of the molecule, each with their own 
strengths and weaknesses. Ultraviolet (UV)/visible absorption detector is in the ultraviolet-
visible spectral region of light. It is the most widely used type of detector in liquid 
chromatography because many organic compounds are absorbed in the UV region of the 
electromagnetic spectrum. Sensitivity of the detector to detect the compound depends on the 
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ability to distinguish it from the liquid solvent, which is mainly in the range of 180 – 210 
nanometers (nm) wavelength. Therefore, a detected compound by an UV/visible detector needs 
to absorb at a wavelength greater than 210 nm. For some compounds, the absorption of light can 
naturally fluoresce. Fluorescence detection is based on the ability to excite the molecule. The 
system is usually set to read the excitation and emission (Poole and Poole 1991). Mass 
spectrometers are used to measure the mass-to-charge ratio (m/z) of a molecule after ionization 
their ability to discriminate by molecular weight (Skoog and Leary 1992).   
 Aspects of Mass Spectrometry  
Mass spectrometers use ion sources and mass analyzers to charge a molecule to an 
ionized or charged state by bombarding the molecule with electrons to produce fragmented ions 
and separate the ion of choice from others using the mass of the molecule. A mass spectrometer 
will sort the ions based on their mass-to-charge ratio. Three types of ion sources are electrospray 
ionization source (ESI), atmospheric pressure chemical ionization source (APCI), and 
atmospheric pressure photo-ionization (APPI) (Pitt 2009). 
The ESI works with moderately polar molecules, such as metabolite, xenobiotics, and 
peptide analysis. The mass spectrometer detects positive or negative ions depending on the mode 
after the sample is pumped into a thin capillary where it is formed into a spray of charged 
droplets. These droplets are evaporated and an electrical charge is transferred to the analyte. 
Many small molecule analytes with a single functional group produce a singly charged ion to be 
detected. Larger molecules or molecules with several charge-carrying functional groups can have 
multiple charged ions (Pitt 2009). 
The APCI functions similarly to the ESI by pumping the sample carried in a liquid 
through a capillary. The charge transfer happens near the tip of the capillary. This source is better 
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for small, thermally stable molecules, which are not ionized well by ESI. This technique works 
for lipids and fat-soluble vitamins (Pitt 2009). 
The APPI is different from ESI and APCI, because it uses photons to excite and ionize 
molecules. The energy from the photons is used to minimize concurrent ionization of the 
solvents in the liquid phase and source gases. This technique is used for analysis of neutral 
compounds like steroids (Pitt 2009). 
After the molecules are ionized, the mass spectrometer uses the ion charge and the 
molecule mass to detect the analyte of interest. Four types of mass analyzers are: 1) quadrupole 
analyzers, 2) time-of-flight analyzers, 3) ion trap analyzers, and 4) hybrid analyzers, each having 
their own advantages of use (Pitt 2009). 
The quadrupole analyzer has a set of four parallel metal rods. The mass spectrometer 
varies the voltage along the rods to allow for scanning across a range of m/z up to 1000 m/z per 
second or more. When coupled with liquid chromatography, a triple quadrupole configuration is 
useful. This is when a collision cell is placed between two quadrupole mass analyzers. A type of 
collision cell is when a quadrupole maintains the low pressure of the collision gas used to 
disassociate or fragment the ions. This increases the specificity of analysis over a single stage 
mass analyzer. When using the triple quadrupole configuration, the first and third quadrupoles 
are stepped to different m/z values simultaneously, where the ion pairs are created to detect a 
large number of target analytes. This common process is called multiple reaction monitoring or 
MRM and is a very common liquid chromatography mass spectrometer (LC/MS) assay. Both the 
single and triple configurations are used in clinical biochemistry applications (Pitt 2009). 
Time-of-flight analyzers use high voltage to accelerate the charged ions. The time it takes 
the ions to travel down the tube depends on the m/z value. This analyzer is highly sensitive and 
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quick with high mass accuracy to allow determination of molecular formulas for small molecules 
(Pitt 2009). 
Ion trap analyzers, using static and radio frequency voltages, trap ions with the three 
hyperbolic electrodes. The ions are released from the trap based on their m/z value. If the 
molecule requires fragmentation, an inert gas is introduced into the trap, which will lead to 
isolation of ions in succession (Pitt 2009). 
Hybrid analyzer is when the third quadrupole is replaced by a time-of-flight analyzer. 
These hybrid analyzers are used for proteomics but have limited scanning ability. Another hybrid 
analyzer is when the third quadrupole is operated in a different mode thereby trapping ions and 
then releasing them sequentially based on their m/z values. This hybrid analyzer is known as a 
linear ion trap referred to as the QTrap instrument. This configuration enhances the sensitivity of 
the ion scanning (Pitt 2009). 
 Coupling with Liquid Chromatography 
Detectors are coupled with liquid chromatography to have an instrument that can 
generate sample throughput in an automated environment. This is accomplished by connecting 
separate systems, which include a pump, an injector, a column, the detector (previously 
described), and waste collection (see Figure 3:1). The pump delivers the solvent to the column 
and then into the detector. The injector delivers the sample with the help of the pumped liquid to 
the column and then to the detector. From the detector, the liquid waste is collected in a 
container and discarded appropriately at the end of the analysis when using an UV/visible or 
fluorescence detector or is pumped into the atmosphere outside the building when using a mass 
spectrometer. Each assay utilizes either an single pump, or two pumps for stepwise pumping 
using two reservoirs with different solvent concentrations (Poole and Poole 1991). 
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The flow rate of the pumping system is dependent on the amount of separation needed 
through the column. Typically, a flow rate of 0.1 to 10 milliliters per minute (mL/min) is used as 
long as the pressure generated by the system does not exceed instrument or column 
specifications. The flow rate of the pump is dependent on the column size and amount of 
separation needed. Three types of pumping systems are reciprocating pumps (90% of 
commercial industry uses this type), displacement pumps, and pneumatic pumps. The 
requirements of the pumping systems are pressure outputs, flow rates, pulse-free output, flow 
control, and flow reproducibility. It is also important that the systems have corrosion-resistant 
components, such as stainless steel and Teflon
TM
. Most systems allow for isocratic flow 
(continuous flow from one reservoir) or gradient flow (step-wise flow of two or more reservoirs 
with a mixing chamber) (Skoog and Leary 1992). 
Solvents are used as the carrier through the stationary phase. The solvents are usually 
termed the "mobile phase" of the system and are liquid or gas as previously discussed. Typical 
solvents used in a mobile phase are water, acetonitrile (ACN), methanol (MEOH), ethanol, and 
chloroform. These are most compatible with the ESI units. The grade of solvent, that is the purity 
of the composition of the solvent, can affect the ability to separate the components in a mixture. 
Buffers, inorganic ions of phosphate or sodium acetate, are common is mobile phases, but should 
be avoided in mass spectrometer applications as they can cause ion suppression. Ammonium 
acetate, formate, or bicarbonate is used instead, but these can also cause some ion suppression. 
Ion suppression is the competition of ions from more than one component, which reduces the 
mass spectrometer signals (Pitt 2009). Therefore, it is important to know and understand how 
each sample reacts in a mobile phase. 
 23 
Baseline resolution, the ability to resolve a peak of interest from the baseline signal, is 
mainly required with using an UV/visible or fluorescence detector, due to the inability of this 
type of detector to separate signals (Pitt 2009). Typical columns range from 10 to 30 centimeters 
(cm) (3.9 to 11.8 inches). Inside diameter ranges from 4 to 10 millimeters (mm) (0.2 to 0.4 
inches). Common particle size is 3, 5, and 10 micrometers (µm).  For a typical separation, a 25 
cm by 4.6 mm column packed with 5-µm particles may be used (Skoog and Leary 1992). Due to 
the ability to separation components based on their mass/charge ratio, mass spectrometers 
generally use smaller columns with particle size less than 2 µm. The shorter the column, the less 
the run time needed to achieve separation (Pitt 2009). Guard columns, a short column placed 
before the column to increase the life of the column and help with the separation, removes 
particulates and contaminants in the solvents. Stationary phase of the guard column is similar to 
the column of choice. Increasing the temperature of the column also helps with separation 
(Skoog and Leary 1992). 
Quantitation of the response (height or area) is the purpose of chromatography. This can 
happen in multiple ways. Normalization method, external standard method, internal standard 
method, and the method of standard additions are four techniques for converting the response 
into relative composition data. Normalization method technique takes the responses gathered and 
sums the response, and then, each analyte is expressed as a percentage of the summed areas. 
Response factors are calculated when the detector response is not the same for all components. 
External standard method techniques use standards at a similar concentration of the anticipated 
sample. The precision of the method is dependent on maintaining constant chromatographic 
conditions throughout the analysis process. The sample responses are compared to the standard 
responses. When a compound is added to the sample at the earliest possible point in the method, 
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this type of technique is the internal standard method. The purpose of the internal standard is to 
compensate for sample loss during the extraction (preparation) to the final chromatographic 
analysis on the instrument. The internal standards for high performance liquid chromatography 
(HPLC) methods are chosen based on their ability to resemble the compound of interest (Poole 
and Poole 1991). For LC/MS applications, it is generally best practice to use isotopically-labeled 
compounds due to identical chemical properties to the analyte of interest and is distinguishable 
during the mass spectrometer analysis (Pitt 2009). The results are calculated based on the ratio of 
the analyte response (height or area) to the internal standard response. This technique helps 
standardize the results of each injection. Without the internal standard, variation is seen between 
injections. The technique of standard additions is not used widely. With this technique, samples 
are analyzed to estimate the concentration (amount) of the analyte in the sample. Then, the 
known amount is subsequently added to each sample, and the sample is analyzed thereby 
showing the approximate incremental increase in the detector response (Poole and Poole 1991). 
Each of these four techniques serves to provide a standardization of the response so that 
quantitation of the sample is determined. The most common practice in industry today is the use 
of the internal standards for analysis of concentration in a biological sample (bioanalysis) and 
external standard when calculating sample potency to determine how long a product can sit on a 
shelf (shelf-life).  
The regulators review the data generated by liquid chromatography during the approval 
process. They rely on the companies to have validated software and instruments when producing 
the data. The industry is required to retain all data generated, either paper records or electronic 
records, for a period of time. The records are maintained appropriately so that the procedures are 
reconstructed when needed. The regulators will go to the company and inspect the records during 
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the approval process. All regulatory requirements are available to the pharmaceutical or biologic 
sponsor through the regulations and associated guidance documents. For biological companies, 
the regulators perform confirmatory testing of the products using the reagents and methods 
supplied by the companies to prove or disprove the results. Regulators inspect facilities and 
study records regularly to ensure compliance with the laws. Companies are expected to cooperate 
fully when the regulators are on site. When issues arise, the regulators issue their findings and 
expect the companies to answer and assure the regulators the issues were addressed. Therefore, it 
is important to follow the regulations and work with the regulators to ensure the products are fit 
for consumption. 
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Chapter 4 - Enzyme-Linked Immunosorbent Assay (ELISA) 
 History 
Enzyme-Linked Immnosorbent Assay (ELISA) is an analytical technique that uses the 
paring of an antigen with an antibody for determining the concentration of either within a 
sample. Several scientists were involved in the development of the radioimmunoassay (RIA), a 
similar technique to ELISA. Rosalyn Yalow and Solomon Berson published a paper describing 
RIA in 1960; however, RIA was not economical and required a large amount of sample that was 
about 5 times as much sample as the ELISA methods require. It required special facilities that 
allowed investigators to work safely with the amounts of radioactivity required. In 1966, L. Wide 
and colleagues published a report highlighting their results from coupling antigens or antibodies 
with enzymes with the idea of using enzyme-labeled antigens and antibodies to detect antibodies 
and antigens by immunofluorescence. Peter Perlmann, a professor at Stockholm University with 
the help of his graduate student, Eva Engvall, were the first to  publish a paper describing a 
method for enzyme-linked immunosorbent assay (ELISA) , in 1971. Perlmann and Engvall used 
the previous knowledge for RIA to create and develop the assay. Their paper described the 
results from quantitative measurement of IgG in rabbit serum with alkaline phosphatase as the 
reporter label (Lequin 2005). 
 Theory 
ELISA is useful in providing measurements of antibody and antigen concentrations, as 
well as, for measuring hormones and other molecules. The assay is specific and sensitive enough 
to detect the presence of antigens that are recognized by an antibody and vice versa. The binding 
of an antibody to an antigen is the essential principle of an immunoassay. This complex 
interaction is exclusive to the antibody/antigen combination. In the body, the antigen will elicit a 
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specific antibody in response. Molecules with large molecular weights can function well as 
antigens, while small molecules, such as drugs, peptides or lipids, require a chemical coupled to 
it in order to elicit the immune response. The epitope is defined as site where the antigen binds to 
the antibody. For binding to occur, the epitope must be available and have the correct shape. 
Antibody affinity is the strength of the interaction at the antigen on a single site. This is usually 
represented as a constant and influenced by factors, such as temperature or pH. In the 
immunoassay, the antibody is detected for a target antigen or analyte. Plasma cells produce 
glycoproteins, antibodies, and function as a binder to foreign or non-self-molecules (Hnasko 
2015). 
 Antibodies 
Antibodies develop in the fetal liver and bone marrow and are produced by B lymphocytes (Wild 
2013). Antibodies are the central part of an ELISA method. These glycoproteins are produced by 
the plasma cells and function to bind to foreign, non-self molecules (Hnasko 2015). The plasma 
cell is the cell in the immune system that is formed after a B cell interacts with foreign material.  
The B cell is genetically coded for a surface receptor to specific antigens.  Once the B cell 
recognizes the antigen, they begin to multiply and produce the plasma cells. Plasma cells then 
produce antibodies (Lamont, Hajishengallis, and Jenkinson 2013). Antibodies have a basic Y-
structure and are also known as immunoglobulins (Ig) (see Figure 4:1). Each immunoglobulin 
has two heavy chains and two light chains. Light chains consist of one variable and one constant 
region, while the heavy chains have one variable and 3 or 4 constant regions. There are five 
classes of immunoglobulins, IgG, IgA, IgD, IgE, and IgM, with IgG as the most abundant. IgG 
immunoglobulins are mainly used in immunoassays. This is because of the abundance in 
production, binding affinity to epitopes, and the ability to withstand the isolation and purification 
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process.  IgM is also used in ELISA assays, but not to the extent of IgG. The remaining 
immunoglobulins are rarely used due to low binding affinity and abundance (Wild 2013). As 
previously stated, there are two types of antibodies, monoclonal and polyclonal, products which 
function similarly in the ELISA assays. Both provide binding of the antigen where the primary 
difference is the number of antigens that are bound (Hnasko 2015).  
 
Figure 4:1 Antigen Y Shape 
(Figure based on Figure 1 page 3 of 214 Hnasko, R. (2015). ELISA Methods and Protocols, 
Springer New York Heidelberg Dordrecht London.) 
 
In an immunoassay, monoclonal antibodies or polyclonal antibodies are used for binding 
of the antigen to the antibody. Monoclonal antibodies are a single antibody directed at an antigen 
epitope. This type of antibody is very specific and usually not hard to obtain commercially. 
Polyclonal antibodies are produced to provide target detection and isolation where there are 
many antibodies able to interact with a single antigen. These antibodies are not in high quantity 
and are reactive with other antigens within a sample (Hnasko 2015). 
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Monoclonal antibodies are harder to produce yet they provide a higher affinity for an 
antigen, giving the assay better specificity. The disadvantage with using a monoclonal antibody 
is if there are subtle changes within an assay, the monoclonal antibody is more vulnerable, that is 
they could react differently in an assay and cause the assay to go through development again. It 
could cause problems with detection of the antigen (Hnasko 2015). Hybridoma technology is one 
way of producing monoclonal antibodies where a mouse is injected with the antigen, and the B 
cells that produce the antibodies are harvested and fused with myeloma or hybrid cell line. 
Monoclonal antibodies are also produced by chemical synthesis, purification, peptide synthesis, 
or recombinant protein expression. Monoclonal antibodies are continuous and renewable, 
limitless due to the ability to grow on cells, generally mouse cells, and can be frozen (Wild 
2013). There is little variation between each production lot. Monoclonal antibodies are readily 
conjugated, linked to a molecule as a label for better detection, and easily characterized (Hnasko 
2015). 
Polyclonal antibodies are easier to manufacture. The antigen is injected multiple times in 
the non-target animal species, generally rabbits. The sera from the animal is harvested, drawn 
during peak antibody production, and then pooled (Hnasko 2015). The quality of the polyclonal 
antibodies depends on the purity of the immunogen as well as the purification process of the sera 
(Wild 2013). The ability of the polyclonal antibody to bind to multiple antigen epitopes increases 
the detection ability. This helps with the vulnerability of the assay. Assays are designed to detect 
certain characteristics of the antibody. For polyclonal antibodies, small changes in antigen 
presentation may not impede the ability to bind. One disadvantage of using polyclonal antibodies 
is that they may have poor binding ability. Another disadvantage is the inability to re-produce the 
polyclonal antibody exactly, thereby disabling the antigen’s detection ability. The sera from the 
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non-target species may produce antibodies; however, the pool may be different or variable in 
some capacity. This may result in a change in the binding ability of the antibody (Hnasko 2015). 
New technology has developed to allow production of recombinant antibodies where 
non-target animals were traditionally used to produce an immune response. These antibodies are 
isolated and cloned. The antibody heavy chains and light chains are fragmented, separated, then 
reproduced and amplified separately.  The light chains are cloned first. Then, cloned heavy 
chains are inserted and linked to the light chains. This synthesized process is advantageous to use 
due to production speed, increase of diverse specificity, elimination of cross reactivity, and the 
optimization of binding affinity and specificity of the antigen. Some disadvantages of this 
technology include limitations of the semi-synthetic gene libraries and fusion proteins are 
describes but not fully available commercially (Wild 2013). 
 Types of ELISA Methods 
Immunoassays function similarly by binding an antigen to an antibody. There are 
different techniques to obtain this binding function. The assays are designed to either detect the 
presence of antigen or test for antibodies that recognize an antigen. The four techniques are 
direct, indirect, sandwich, and competitive (see Figure 4:2).  
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Figure 4:2 Schematic of ELISA Techniques 
(Figure based on Figure 1 page 2 of 8 Heiat, Mohammad, Reza Ranjbar, and Seyed Moayed 
Alavian. “Classical and Modern Approaches Used for Viral Hepatitis Diagnosis.” Hepatitis 
Monthly 14.4 (2014): e17632. PMC. Web. 9 Apr. 2017.) (Ag is antigen) 
 
Direct ELISA methods use passive absorption of the antigen of interest to the microtiter 
plate. Direct methods are useful to qualitatively or quantitatively measure the antigen in the 
sample. It also is used for antibody screening and epitope mapping. One advantage to the direct 
ELISA method is the lack of cross reactivity in the microtiter plate. The antigen only binds to a 
single antibody. As a result, the assay is performed in less time. The assay is useful to analyze 
for epitope mapping and antibody screening (Hnasko 2015). 
Indirect ELISA methods are similar to direct with the exception of the use of a secondary 
antibody. The secondary antibody is used to amplify the signal of the primary antibody bound to 
the antigen. The primary antibody is unlabeled, that is linking the antibody to an enzyme. An 
anti-species enzyme-conjugated secondary antibody is added to the microtiter plate and binds to 
the primary unlabeled antibody. The enhancement of the primary antibody signal makes the 
method more sensitive that direct ELISA methods. A disadvantage to the method is that a higher 
background signal is produced and can decrease the overall net signal of the assay (Hnasko 
2015). It also may have more non-specific binding to interfere with the signal; therefore, the 
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purity and specificity of the antigen bound to the microtiter plate are critical components when 
evaluating specificity of the ELISA method (Wild 2013). 
Sandwich ELISA methods use two antibodies to bind to different sites of the antigen. The 
primary antibody, or capture antibody, is bound to the microtiter plate. The microtiter plates are 
usually commercially available 96-well polystyrene plates. This primary antibody is highly 
specific to the antigen of interest. Samples containing the antigen, or analyte, are added to the 
plate. Conjugated, attached, detection antibody follows the sample addition. The detection 
antibody is conjugated to an enzyme. The result, the antigen is sandwiched between the primary 
antibody and the detection antibody (Wild 2013). This type of assay is very common due to the 
sensitive, precise, and robust format. However, the disadvantage is the antigen must have two 
different epitopes to bind with (Wild 2013). Sandwich assays are ideal animal safety samples 
(Hnasko 2015). 
The final assay technique used for ELISA is competitive. This is based on direct, indirect, 
or sandwich ELISA methods. They are very complex methods and are called inhibition ELISA 
methods. Used mainly for the detection of small molecules with low molecular weights, the 
assays rely on enzyme-linked antigens to bind and compete with the antigens of interest in the 
microtiter plates. Signal detection is inversely related to the quantity of an antigen in the sample. 
The sensitivity of the assay is defined by equilibrium constant of the antibody, the precision of 
the signal measured, and the level of the non-specific binding. Therefore, it is not as sensitive of 
an assay as direct sandwich. An advantage for using competitive ELISA is the purification of the 
sample is not needed. One disadvantage to competitive ELISA methods is the timing of the 
incubation steps. These are critical to reproducibility of the assay. Small molecules, such as 
steroids, work well with this technique (Wild 2013). 
 33 
 ELISA Methods 
 Each assay is designed in a way to optimize the detection of the antigen or antibody. It 
starts with determining the reagents needed in the assay. The antigen-antibody binding affinity is 
maximized to create an environment where they are most adapted to each other. The antigen-
antibody binding affinity is measured by the dissociation equilibrium between the two, the lower 
the dissociation between the antigen and the antibody the stronger the binding affinity. 
Determination of which antibodies work best for capture or detection is crucial to the 
performance of the method. These two roles are interchangeable. Each method should determine 
which role the antibody is best suited. If the method requires a capture antibody, the capture 
antibody is added to each well of the 96-well microtiter plate. It is bonded to the plastic of the 
plate by non-covalent bonds between the hydrophobic proteins and the plate surface. Blocking is 
the next step of the method and is essential to reducing non-specific binding of the primary or 
secondary antibodies to the solid surface of the plate. Washing buffers are added to the plate to 
remove any biological or chemical interfering components that may reduce assay signal. Wells 
of the plate should remain moist during most of the assay in order for the wash steps to be 
effective. The secondary antibody is added and is used to generate a signal. They are usually 
enzyme-labeled and are purchased commercially or produced by the company. These induce 
signal amplification as previously stated (Wild 2013).  
 The two most commonly used enzymes are horseradish peroxidase (HRP) and alkaline 
phosphatase (ALP). These enzymes are conjugated to either the primary or the secondary 
antibody, that is the labeling of the antibody, and are used in the detection of the antibody stage. 
Conjugating the primary antibody can be difficult because it lacks signal amplification and 
results in weak or no signal for detection which is why many assays conjugate the secondary 
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antibody. When this is the case, the conjugation of the secondary antibody allows for the primary 
antibody detection without direct conjugation. A substrate solution is added for color 
development. HRP and ALP require different substrates to produce light. Substrates tetra-
methylbenzidine (TMB), 3, 3’-diaminobenzidine (DAB), and 2,2’-aziro-bis (3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) are recommended for HRP conjugate while 
chromogen p-nitrophenyl phosphate (PNPP) is recommended for ALP. After the substrate 
solution is added, the stopping solution is added to stop the chemical reaction of the substrate 
with the enzyme. At this point, the microplate is placed on a spectrophotometric plate reader, 
where a specific wavelength of light is transmitted through the microtiter plate and the 
absorption of light is read (Wild 2013). 
 Methods may include either a positive control or negative control sample. These samples 
are manufactured in the same manner as the product. Positive controls include all components of 
the product while negative controls remove the antigen or antibody of interest. These controls are 
used in methods for acceptance of the readings due to the known quantities of antigen in the 
positive controls or the lack thereof in the negative controls. The criteria of these are determined 
during development and validation of the assays. If either of these have a result that is not 
expected or outside validated criteria, the data is deemed not reliable then testing is repeated. If 
the results are within acceptable limits the second time, the data is usually accepted and reported. 
If the results show a similar unexpected trend, the data and assay are investigated to find the 
cause of the erroneous result(s). These controls help show assay reliability and reproducibility 
and ensure a rugged method by ensuring no false positive or false negative responses are 
reported. 
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 Many plate readers are commercially available. Perkin Elmer VICTOR
TM
 X3 Multilabel, 
Berthold LB962 CnetroPRO, and Molecular Devices Spectromax are some examples. For 
regulatory compliance, the instrument is validated, that it is tested several times and produce the 
desired result within a specified tolerance each time. The industry is moving towards instruments 
that are considered GXP where the X represents laboratory or manufacturing so that the software 
is valid for either Good Practice regulation. The data generated by a plate reader is in absorbance 
readings or optical density based on the wavelength used. The wavelength is determined during 
the development and validation of the assay. The absorbance readings or optical density are then 
quantifiable when transferred to a calculation software, usually excel, or some other system. A 
report is generated to show the method used and the outcome of the testing.  
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Chapter 5 - Flow Cytometry 
 History 
Flow cytometry is the study of physical or chemical properties of cells. These properties 
or characteristics are then measured (Shapiro 2003). Since cell discovery in the 1600’s, 
information about cells has expanded, such as structure and complexity as well as function 
within a cell and different cell types. In the 1800’s, cell theory and germ theory were published. 
Cell theory is the idea that cells are the fundamental structure and functional unit in living 
organisms that propagate from other cells and is the foundation of modern biology. Germ theory 
is the development of disease by microorganism growth. Cells were observed and researched 
through the use of microscopes (Herzenberg et al. 2002). Around 1934, Moldovan developed a 
photoelectric method for counting individual cells while flowing through a capillary tube 
mounted on a microscope. These tubes unfortunately were problematic due to size. The tubes 
were difficult to manufacture to a standard size or flatten for ease of viewing under the 
microscope (Moldovan 1934). Later, Gucker et al. developed an instrument for the analysis of 
dust, which was also used for the study of microbiological specimens. This instrument was used 
by the U.S. Army to detect airborne bacterial spores during World War II (Gucker et al. 1947).  
In the mid 1950’s, Wallace Coulter wanted to measure cell volume, and subsequently, developed 
a flow instrument. This instrument, deemed Coulter Counter, determined the number of cells in a 
suspension. The Coulter Counter measured the electrical conductivity difference between the 
cells and the suspension medium (Robinson 2013). The 1960’s was the decade in which the first 
flow cytometer was made available with the ability to quantitatively measure the physical and 
chemical properties of cells. Cell sorters were also developed during this time period 
(Herzenberg et al. 2002).  
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Mack Fulwyler at Los Alamos National Laboratories and Dr. Louis Kamentsky at IBM 
enhanced their flow cytometers to include a cell sorter. Kamentsky’s instrument included a 
syringe pump, while Fulwyler’s used an ink jet printer. Injected samples followed through the 
measurement system to be atomized into droplets. Each droplet with cells was electrically 
charged. The electrically charged particles within each droplet were collected in a vessel, while 
the remaining uncharged particles went to waste. Next, the use of fluorescence measurement to 
improve both the quantitative and qualitative analyses was implemented. Kamentsky left IBM to 
start Bio/Physics Systems, where the first fluorescence flow cytometer with an argon laser was 
built (Shapiro 2003). Fluorescence Activated Cell Sorter (FACS) was invented by Bonner, 
Sweet, Hulett, Herzenberg, and others. This instrument was and is used today for flow cytometry 
and cell sorting on viable cells, such as blood cells or organ cells. By the 1970’s, Becton 
Dickinson Immunocytometry Systems introduced commercial machines with the help of the 
Stanford patent (Herzenberg et al. 2002). The optic improvements during this time period, along 
with the development of better fluorescent stains, lead to the use of the flow cytometer in the 
research of cells.  
In the industry, flow cytometry is used as an analytical technique to provide support 
testing for products. Although, mainly used in the human health testing under medical device 
regulations, it is beginning to gain use in the animal health industry. It provides a way to test for 
biomarkers after administration of a biological product to test for immune response or 
pharmacodynamics responses after administration of a pharmaceutical product. 
 Theory 
Flow cytometers use electrical and/or mechanical means to divert or collect cells of 
programmed characteristics. These instruments analyze the physical and chemical characteristics 
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of particles within a fluid stream as it passes by at least one laser. A single cell per second, up to 
thousands of cells per second, can be analyzed during the analysis of a sample. Each instrument 
is comprised of three main parts: the fluidics, the optics, and the electronics. See Figure 5:1 for 
flow cytometry diagram. 
 
Figure 5:1 Diagram of Flow Cytometry Instrumentation 
 
Flow cytometry measures the energy emitted by the photons after the laser lights up the 
cell. Photons are pure electromagnetic energy, where the absorption or emission of these by 
atoms or molecules is the only mechanism by which they are able to gain or lose energy. 
Electromagnetic radiation, or light, detects photons and behaves similar to a wave traveling at the 
speed of light. Light is emitted at wavelengths between 400 and 700 nanometers (nm). Using 
frequency or wavelength, the energy of a single photon is calculated. Photons were derived from 
incandescent sources, where temperature increases can cause the incandescent object to shift 
toward a high modal value and produce light (Shapiro 2003). 
An alternative to incandescent objects is the use of a laser. A laser does not require 
incandescence to product light. It was previously determined that light interacts with matter in 
the electric field vector, and is the basis for all calculations (Shapiro 2003). 
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The flow cytometry principle is based on light scattering, more importantly, on Mie 
scattering seen in Figure 5:2. This principal, named for Gustav Mie, explains the process of light 
that is scattered in the forward direction. Flow cytometry measurements on cell size are based on 
this principal. Mie scattering involves interference, where light scatters by both reflection and 
refraction at the surface (Shapiro 2003). 
 
Figure 5:2 Mie Scattering Diagram  
(Figure based on Figure 1 page 2 of 8 Malvern Instruments (2016). Mie theory: the first 100 
years. United Kingdom, Malvern Instruments Limited.) 
 
Absorption of the photons raises the molecule to a higher-energy excited state from its 
minimum-energy ground state. This change is called transition. Absorption of light by an atom or 
molecule produces electronic transition.  Fluorescence of the atom or molecule causes the cell to 
emit all of some of the photons remaining for detection by the instruments as they approach their 
ground state. This is accomplished by fluorescent probes or dyes (Shapiro 2003). 
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 Flow Cytometry Components 
 Fluidics system 
The fluidics portion of the instrument is the stream of fluid used to transfer the sample 
containing the cells to the laser. Two components of the fluidics system are sheath flow and 
pressurized lines. The sheath flow, or hydrodynamic focusing, centralizes the sample, or core 
fluid, containing the cells to the central portion of the flowing stream. Flow requires stability 
through the whole process that is in a laminar flow pattern. Sheath fluid is pressure driven. Water 
is not ideal for the fluid of choice due to its high viscosity. However, phosphate-buffered saline 
or PBS is commonly used. Samples align in single file due to the pressure difference between the 
sheath fluid and the sample stream.  Therefore, it is essential to keep the sheath flow debris free 
so the flow is not obstructed (Shapiro 2003). Flow rate of the sheath fluid can vary. The flow can 
be high for common applications, such as immunophenotyping of mammalian cells, or slow for 
quantitation of DNA content in fluorescent-stained nuclei. For the best uniformity and accuracy 
by the laser beam, slow flow rates are recommended (Wilkerson 2012). 
 Optics System 
The optic system is where the laser illuminates the particles present in the fluidic stream 
as they pass through the instrument and scatter the light. This optics system uses lenses, glass, 
plastic or quartz, with a shape that makes rays of light reach a distant point. Lenses are used to 
decrease or increase the size of the image. A photon streaming along an optical axis is guided by 
the lens. The lens is convex in design where the material is of refractive index greater than that 
of air, and the center is the thickest (Shapiro 2003). 
The laser is used as the light source because it is generally confined to the very small 
solid angle with the ability to focus all of the energy in the beam. The laser beam is directed at 
 41 
the lens in the flow cytometer. Argon ion lasers are popular with flow cytometry for their 
fluorescence. Air-cooled argon-ion lasers are the most commonly used flow cytometry laser in 
the industry. Krypton ion lasers are another type that functions similarly to the argon-ion. 
Krypton lasers do not emit the same wattage of light as argon; 1 watt of light with krypton 
compared to 5 watts of light with argon. Other lasers include dye laser, helium-neon, diode lasers 
and more.  These can pose some health risks where argon lasers do not. Argon-ion lasers usually 
operate at a wavelength of 488 nm. Plasma is the lasing medium, which is pulsed at high-voltage 
to ionize the gas to start the plasma. Argon ion lasers are suitable for measurements of weak 
fluorescence. Laser noise, background noise of the instrument readings, can come from a variety 
of sources. “Noise eaters” minimize the noise and are placed in between the laser and the rest of 
the mechanisms or by a noise compensation circuit which is more costly than the noise eaters 
(Shapiro 2003). 
Optical filters are used to detect spectral responses in the flow cytometer. Filters are 
helpful in removing unwanted light wavelengths and direction of the wanted wavelengths to the 
detector. An enhancement to the flow cytometer was the use of monochromatic or polychromatic 
detectors. Monochromators divert different wavelengths of light into different directions then 
positioning a slit between the gating and the detector. Multiple polychromatic detectors are 
placed along several regions of the image. Despite this new technology, filters are the most cost 
effective option (Shapiro 2003).  
The light is collected and is detected by detectors. On type of detector is a photodiode, 
which does not require an external power source and usually operate in the photovoltaic mode. 
Photodiodes converts light into current and are more efficient. Photomultiplier tubes are another 
type of detector where the tubes produce current at the anodes when photons reach the light-
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sensitive photocathodes. They require shielding from stray light and magnetic fields. 
Photomultiplier tubes are used as detectors for weak signals, such as fluorescence scatter. Also 
available is the avalanche photodiode, which combines both the properties of photodiodes and 
photomultiplier tubes. Photomultiplier tubes, however, are the most desirable (Shapiro 2003). 
 Electronics System 
The electronics system changes the detected light signals into electronic pulses for the 
computer to process. The instrument recognizes that the cell is present. When the cell is not 
present and not passing through the observation point, the response output is the background or 
baseline noise. Once the cell is acknowledged as present by the system, a pulse appears. The 
response remains active until the signal drops below the specific threshold. The output is either 
linear or logarithmic (Shapiro 2003). 
To measure the cells, three physical parameters are measured. These are forward and side 
light scattering and fluorescence, see Figure 5:3. In forward angle scatter, the light is diffracted, 
or the process by which a beam of light is spread out, around a cell and proportional to the cell 
size. Sid angle scatter is at 90 degree angle and is proportional to the internal complexity of that 
cell. The light scatter properties help distinguish each cell based on their size and internal 
complexities (Wilkerson 2012). Fluorescence is the loss of some of the absorbed energy of the 
photons by light emission. This happens after the molecule first absorbs light at a wavelength 
shorter than or equal to the emitted light resulting in an excited electron state. The emission 
occurs at a wavelength that is longer than the excited wavelength (Shapiro 2003). 
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Figure 5:3 Forward and Side Light Scatter 
(Figure based on Figure 3-1 page 10 of 52 Dickinson, B. (2002). Introduction to Flow 
Cytometry: A Learning Guide. Becton Dickinson and Company.) 
  
 Reagents 
Not all samples analyzed by flow cytometry require the addition of reagents prior to 
analysis. However, some reagents are needed to help with analysis of the samples. For those 
samples that need to distinguish the different types of cell structures, the reagents, called probes, 
are added to the sample to bind to the structure of the cell of interest. They are essential in 
providing the means from which the detection of the cells happens. Probes, or fluorochromes, are 
added to the samples to help with the light absorption. Fluorochromes are used to label proteins, 
nucleic acids, and reporter molecules. Synthetic and natural dyes are available. Natural dyes 
include algae and phytoplankton. These are excited by an argon laser and results in a higher 
wavelength for emission. Synthetic dyes include fluorescein isothiocynate (FITC) and 
phycoerythrin (PE). FITC, excited by the argon laser, will emit in the green spectrum, 535 nm, 
while PE will emit in the orange spectrum, 585 nm (Wilkerson 2012). 
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When the sample is a whole blood sample, the blood needs is collected so that there is no 
cell activation (that is the activation of the immune response and cell division), death, or 
aggregation. Using K2EDTA (Dipotassium ethylenediaminetetraacetic acid) anticoagulant in the 
collection tube will keep the cells from changing before analysis. After collection but prior to 
analysis on the instrument, the addition of the fluorescent-labeled antibody is added. The red 
blood cells are removed by the addition of a lysis buffer. Each type of sample requires a method 
specialized to it. For analysis that requires a labeled intracellular antigen, cells are made 
permeable by the addition of a permeable agent that will allow the antibody to enter the cell. In 
animal health, secondary conjugated antibodies are mainly required because primary antibodies 
are not as readily available (Wilkerson 2012). 
 Flow Cytometry Results 
In order to gain understanding of the data, results are usually graphically displayed. The 
electronic system of a flow cytometer sends the pulse data to a computer with software capable 
of producing the numbers as well as graphs. Frequency distributions, or histograms, are used to 
examine the measured values of cell parameters. Single parameter analysis was widely used due 
to restrictions of the instrument. Recently, two parameter or multicolor analyses are available.  
For multicolor and two parameter data, dot plots or scatter plots are used to show relationship 
between parameters/colors. Generally, the pulse data is collected into bins. The binned data is 
then used to produce the distribution of the measured values. The dyes or stains are added to help 
identify the different phases of the cell cycle as well as the cell behavior and chemical 
composition (Shapiro 2003). See Figure 5:4 for flow cytometry results display. Here the scatter 
plot shows on the x-axis the forward scatter and the y-axis is the side scatter of the cells. When 
the cells are dense, these are considered small cells because they are compact, the lower part of 
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the scatter plot. Larger cells are not as densely displayed, the middle of the scatter plot. After the 
cells are initially read by the instrument, the computer software is used to segregate a population 
of cells by refining the gating. With each refinement, the scatter plots reveal more about the cells 
of interest. 
 
Figure 5:4 Results Displayed by Flow Cytometry 
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Chapter 6 - Practical Uses 
In the animal health industry, analytical techniques are used for a variety of applications. 
Figures 2:1 and 2:2 showed the timelines for the product development. Each company is 
responsible for developing and validating the methods used when submitting reports for market 
approval. Guidelines provide direction on governmental expectations of the methods. 
 Each method is to describe the chemicals and reagents, instrumentation, concentrations, 
and more in order for the analysis by the method. Acceptance criteria of the run is either included 
in the method or in Standard Operating Procedures provided by the company and are in line with 
regulations.  
 GMP Analysis (Title 21 of the CFR parts 210 and 211) 
For Active Pharmaceutical Ingredient and veterinary product, analytical procedures are 
used. These procedures test for purity of the API and product or potency of the vaccine, as well 
as stability of the product during storage at the warehouse or in a home, which is considered 
shelf-life. The results of the testing are recorded in a Certificate of Analysis for each lot or batch 
of product. This document describes the tests conducted, and the results of the tests to show the 
quality of the product and leads to shelf-life of the product.  For an API or drug product, the 
testing is evaluated using LC/MS techniques. Stability testing for shelf life gives each product an 
expiration date as it awaits distribution.  
 GLP Analysis (Title 21 of the CFR part 58) 
When determining safety of a pharmaceutical product, the testing is conducted as 
bioanalysis. These methods are developed to show the concentration of the compound through 
dosing time. The test protocols are designed to determine the length of time for the drug to move 
through the animals system and be eliminated. This is to make sure the drug is not given at too 
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high of level to cause an adverse reaction, such as death. These bioanalytical methods are 
described and include the chemicals and reagents, instruments, standard concentrations necessary 
to determine sample concentration. LC/MS is a typical technique used for small molecule 
bioanalysis. Small molecules are drugs with low molecule weights, such as Aspirin with a 
molecular weight of 180 g/mol. Molecules with high molecular weights are considered large 
molecules. These are molecules based on proteins with a molecular weight as high as 150,000 
g/mol. These can be analyzed by LC/MS or HPLC, as well. ELISA is generally used for these 
types of compounds. Each method is specific to each compound.  
 USDA Biological Analysis (Title 9 of the CFR) 
Sometimes the analysis is not limited to the analyte or organism, such as bacteria or virus 
of interest. In some cases the technique is used to analyze the reagents of the test method. When 
using an ELISA to test for the antigen of interest in a vaccine, the reference material, conjugate, 
monoclonal or polyclonal antibodies, and more critical reagents are analyzed and compared to 
the previous batch to ensure the method is producing results similar to the originally validated 
method. These analyses help to keep the method uniform. Reference material for use in vaccine 
testing is usually stored for an extended period of time. To ensure the reference material has not 
degraded over time, the material is analyzed and compared to itself after several analyses and 
trending is reviewed. If the trend does not show an increase or decrease over time, the reference 
material is considered stable. The reference material is used during analysis of the vaccine 
sample to ensure the newly produced vaccine is within the potency guidelines. The target of the 
vaccine production is to have a response equal to or greater than the reference material.  
Reference material for vaccine production has several requirements for stability. One 
determination of stability is the back comparison to the analyzed data collected over the life span 
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of the storage. Another way to support the stability of the reference material is by development 
other analytical techniques. One technique for stability evaluation of the reference material is the 
use of LC/MS. The reference material is analyzed on the instrument and compared to the 
historical data with trending. Trending is the study of the material over time. The reference 
material is evaluated every 2.5 years to see if it behaved similar between each use. If the data 
trends up or down from the average, the methods and the reference material are investigated to 
determine the problem. If the method is found to have little changes, the reference material is 
changed to a new lot and compared with the historical data of the old lot for assay results. VSM 
200.211 guides the process and expectations to follow. 
Stability of the vaccine is also determined by assay techniques. The product stability is 
tested with ELISA using current reference materials and reagents or by other assay techniques; 
however, the other techniques are not addressed in this report. When the results of the stability 
test are within the guidelines, the test is accepted. 
 Other Analyses 
In the industry, flow cytometer use is for analysis of cells of a sample. Typical analysis 
for samples is to count the viable cells of interest. The instrument sorts the cells, and then, it 
evaluates the number of cells based on approved protocols. Protocols, such as determination of 
DNA, immunological studies, and stages of cell death, are developed. Flow cytometry is quickly 
gaining acceptability within the animal health community. Immunological studies use flow 
cytometry for determination of T lymphocytes and the roles they play in autoimmune diseases.  
Biomarker analysis is another type of analysis a flow cytometer can produce. This type of 
analysis is used to characterize an animal sample by objectively measuring and evaluating to 
indicate the normal biological process, pathogenic process, or pharmacologic response to a 
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therapeutic intervention, such as pharmaceutical product or vaccine administered for the health 
and wellbeing of the animal. A vaccine would illicit a normal biological response because it 
encourages antibody production in the presence of antigen. Disease is the outcome of a 
pathogenic process after infection with a bacteria or virus when these replicate within the body. 
The biochemical or physiological effects of a treatment by a pharmaceutical product is a 
pharmacological response.  Biomarkers are associated with each type of assay and are evaluated. 
This analysis is used in support of the drug or vaccine getting to market.  
Modern flow cytometry is a useful tool in diagnosing of cancer or other health problems 
at the cellular level. The instrument can detect changes in the cells when compared to a normal 
cell and show what stage of cancer a small animal, such as a dog, might have if diagnosed with 
lymphoid neoplasia or leukemia. 
Each of these assay protocols would be used to provide qualitative data in support of the 
approval process.  In the next chapter, some practical examples are provided to describe how 
each technique is applied in the animal health industry. 
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Chapter 7 - Practical Examples 
 Liquid Chromatography with Tandem Mass Spectrometry to measure 
Zilmax
®
 (Merck Animal Health) in cattle urine and faeces 
Beta-agonists are useful in the health and welfare of animals to help fatten the cattle prior 
to processing. Beta-agonists belong to the chemical class of catecholamine and bind to beta-2-
receptors to stimulate the receptors to relax the muscle. Also used as bronchodilators to treat 
pulmonary diseases such as asthma in humans, these drugs improve carcass composition as the 
animal decreases their fat content in favor of muscle. The drug product is given as a low dose to 
cattle to help fatten the animal by allowing the animals body to focus on turning feed into muscle 
The European Union (EU) has banned the use of beta-agonist products. A product produced by 
Merck Animal Health called Zilmax, or zipaterol, is a beta-adrenergic agonist compound that is 
different from the well-known N-alkyl-beta-agonists and di-aromatic beta-agonists due to its 
chemical structure. Zilmax is given to cattle in their feed to help promote better muscle gains. A 
LC/MS method was developed for concentration of zipaterol in cattle urine and feces to help 
determine the elimination withdrawal time (Hoof et al. 2004). 
Chromatographic separation of zilpaterol in urine was achieved by LC/MS using the 
following components. The column was Inertsil ODS C18 (3 micrometer particle size, 3.0 mm 
diameter by 100 mm in length). A gradient pumping scheme was deployed with a mixture of 
water and MeOH in the presence of ammonium acetate for 25 minutes total run time. The flow 
rate was set at 0.6 mL/min. The mass spectrometer was set to MS
3
-mode, which is triple 
quadrupole mode. Zipaterol in feces was achieved by LC/MS using an Alltima C18 (5 
micrometer particle size, 3.5 mm diameter by 250 mm in length) column with isocratic pumping 
at 0.5 mL/min for 4 minutes total run time. The mobile phase was a mixture of 
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pentafluorpropionic acid and acetonitrile. The mass spectrometer was set to MS
2
-mode, which is 
also a triple quadrupole mode. Both methods gave results that were reproducible for testing of 
urine and feces after the oral administration of Zilmax to male veal calves (Hoof et al. 2004). 
 Enzyme-Linked Immunosorbant Assays to measure antibodies following 
vaccination with a new vaccine candidate in sheep 
 Bluetongue disease is monitored by the World Organization for Animal Health (OIE) due 
to the increase in transmission rate due to the environmental changes and economic loss due to 
the loss of trade for those animals that are infected. This disease is caused by a virus (bluetongue 
virus) and transmitted by Culicoides biting midges. Midges are a group of insects that includes 
small flies. Bluetongue disease causes significant economic loss to cattle and other ruminant 
farmers. Bluetongue virus (BTV) is usually a temperament climate organism; however, it was 
recently discovered in areas of milder climate. Vaccination for BTV is the most effective way of 
controlling outbreaks of the disease. Vaccines are currently available as both live attenuated or 
killed inactivated products. A new novel product for vaccination was developed. This uses the 
Disabled Infectious Single Animal (DISA) concept, in which this platform has removed the 
NS3/NS3a expression. NS3/NS3a is a non-essential protein which is synthesized in the BTV 
replication. This platform has the advantages of the live attenuated vaccines without the risks of 
viremia, or the presence of virus in the blood (Tacken et al. 2015). 
 To determine the presence or absence of BTV after vaccination and challenge, a 
competitive ELISA method was developed. The NS3 was produced, then tagged and purified. 
The purified NS2 tagged antigen, monoclonal antibody 33H7, and rabbit alpha-mouse serum 
conjugated to horseradish peroxidase were used to coat the maxisorp plates and incubated 
overnight at 4°C.  Prior to incubation, a solution of phosphate buffered saline (PBS) with 0.01% 
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Tween 20 and 5% fetal bovine serum (FBS) was used to coat the wells to reduce non-specific 
binding. The collect sera from the animals was diluted with the PBS/Tween/FBS solution and 
added to the wells then incubated again. The plate was washed to remove unbound sera 
antibodies. Monoclonal antibodies were added and the plate was incubated. The plate was 
washed and conjugated rabbit alpha-mouse serum was added. After incubation, TMB substrate 
was added and color development was stopped with addition of a stopping solution. Optical 
density was read at 450 nm. The results of the study showed the ELISA assay detected BTV 
infections after vaccination and challenge for BTV serotypes 1-24. The ELISA test is not 100% 
sensitive or specific for antibodies directed against BTV NS3; however, it is a good tool to 
monitor DISA vaccinated populations for BTV circulation (Tacken et al. 2015). 
 Flow Cytometry to measure IFNγ Expression after vaccination in cattle 
 Bovine tuberculosis has caused significant economic loss; for British taxpayers it costs 
£100 million (~$107 million U.S. dollars) each year. In 2016, bovine tuberculosis caused the 
slaughter of 28,000 cattle for control of the disease (Leadsom 2016). This global disease problem 
for animals is considered an increasing economic issue for the future; therefore, vaccination is 
needed to effectively fight against outbreaks. A better understanding of the protective immune 
response to the disease will help with development of a vaccine. Memory CD4 T-cells were 
identified and defined in cattle. Four distinct CD4 T-cell populations were purified by cytometric 
cell sorting and purified (Blunt et al. 2015). 
 Six Holstein-Friesian cattle were used in the study. Three were given the vaccine, and 
three were considered naturally infected. The study was designed to determine if there is a 
difference between responses of vaccinated or naturally infected cattle. 
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Cattle blood was collected and the peripheral blood mononuclear cells were prepared 
from peripheral blood by gradient density centrifugation, and the CD4
+
 T-cells were enriched by 
paramagnetic bead isolation using monoclonal antibody CC8 (IgG2a). The CD4
+
 T-cells were 
then stained with monoclonal antibodies CC32 (IgG1) and IL-A116 (IgG3). A second staining 
was done with rat monoclonal antibody to mouse IgG1 (brilliant violet 421), goat anti-mouse 
IgG2a (FITC), and goat anti-mouse IgG3 (R-phycoerythrin). The cells were incubated, washed, 
and re-suspended in RPMI 1640 medium used to culture cells in a suspension. Next, the cells 
were passed through a 30 micrometer filter for sorting. The flow cytometer was set at 60 psi with 
a 70 micrometer nozzle. After sorting, the cells were greater than 98% pure for each of the four 
populations (Blunt et al. 2015). 
 The sorted CD4 T-cells were evaluated for cytokine response. The flow cytometry results 
prior to sorting showed the majority of cells expressed cell surface CD45RO. The sorted cell 
populations were used in the experiments to show the different cell populations in vaccinated and 
infected animals. The cells were stimulated in vitro to show the frequency of IFNγ secreting 
cells. Additional flow cytometry analysis was performed to test for CD4 T-cell plasticity during 
culture. Plasticity is defined as the switch phenotype that is up- or down- regulated within 
stimulation (Blunt et al. 2015). 
 The study used the flow cytometry data to support the testing ex vivo ELISPOT. The in 
vitro testing of the cells surface markers showed plasticity, which would make it difficult to 
directly correlate the observed ex vivo results (Blunt et al. 2015). 
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Chapter 8 - Conclusion 
The animal health industry continues to grow as the demand of the importance for the 
welfare of the animals continues. There are many animal health products available for purchase 
to help in multiple therapeutic areas. These products go through rigorous testing to prove their 
viability for use before marketing approval. The top animal health companies spend billions of 
dollars and many years developing products following the governmental regulations and 
guidelines. The regulations enacted to enforce each law by the U.S. government depend on 
which type of product is marketed. 
Pharmaceutical products for animal care are governed by the Center of Veterinary 
Medicine (CVM) of the Food and Drug Administration (FDA). The CVM follows Title 21 of the 
CFR, the regulation based on Title 21 U.S.C., the Federal Food, Drug, and Cosmetic Act. The 
Federal Food and Drugs Act of 1906 was enacted to ban interstate transportation of adulterated 
or misbranded food or drugs. Title 21 of the CFR gives guidance and expectations the FDA 
regulators inspect against when determining if a product is ready for marketing. They will 
inspect for compliance with Title 21 of the CFR Part 58 for GLP analysis and Parts 210, 211 or 
226 for GMP analysis and all associated guidance for the industry documents.  
Biologic products, such as vaccines, bacterins, and antisera, for animal welfare are 
governed by the Center for Veterinary Biologics (CVB) of United States Department of 
Agriculture (USDA). The CVB follows Title 9 of the CFR, the regulation based on Title 21 
U.S.C., the Virus-Serum-Toxin Act. The Virus-Serum-Toxin Act of 1913 was enacted to provide 
the government the ability to give license for biological products as well as regulate trade of 
those products biologics. The regulators inspect each product license application for safety and 
efficacy of the product for the target animal. The regulators will inspect each application against 
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the Title 9 to the CFR and associated veterinary service memoranda to determine if the product 
met the requirements to show its purity, safety, potency, and effectiveness. 
 In order to fulfill the testing requirements, companies are asked to validate testing 
protocols or instrumentation methods. Analytical techniques for testing include high 
performance liquid chromatography (HPLC), liquid chromatography with tandem mass 
spectrometer (LC/MS), enzyme-linked immunosorbent assay (ELISA), and flow cytometry. 
Each technique has several components to make the assays work. Depending on what the need 
is, the technique is used for practical applications. Analytical analysis employs the use of HPLC 
or LC/MS for determining stability of the active pharmaceutical ingredient or drug product shelf 
life. Bioanalysis for determination of concentration versus time in sampling employs HPLC, 
LC/MS, and ELISA. Vaccines use ELISA and LC methods when determining reference material 
stability and critical reagents as well as potency and shelf life. When a study protocol requires 
more information, flow cytometry could be used to detect cellular biomarkers.  Animal health is 
dependent on the accuracy of these analytical methods to show the regulators the usefulness of 
the product and ensure the regulators the products are safe and efficacious to treat animal health 
and welfare. 
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Appendix A - Acronyms 
Acronym Full Description 
U.S. United States 
CVM Center for Veterinary Medicine 
CVB Center for Veterinary Biologics 
FDA Food and Drug Administration 
USDA United States Department of Agriculture 
APHIS Animal and Plant Health Inspection Service  
API Active Pharmaceutical Ingredient 
ELISA Enzyme-Linked Immnosorbent Assay 
LC Liquid Chromatography 
CFR Code of Federal Regulations 
U.S.C. United States Code 
OIRA Office of Information and Regulatory Affairs 
NPRM notice of proposed rulemaking  
GFI Guidance for the Industry 
VICH Veterinary International Conference on Harmonization 
CMC Chemical Manufacturing and Controls 
INAD Investigational New Animal Drug 
FOI Freedom of Information 
NADA New Animal Drug Application 
VSM Veterinary Services Memorandums 
DHS  Department of Homeland Security 
PLA Product License Application 
SIF Summary of Information 
GMO  Genetically Modified Organism 
DOI Duration of Immunity 
PLS Prelicensing Serial 
FST Field Safety Trial 
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Acronym Full Description 
GLP Good Laboratory Practices 
GMP  Good Manufacturing Practices 
PCR polymerase chain reaction  
qPCR quantitative reverse transcription PCR  
RNA Ribonucleic acid 
NMR nuclear magnetic resonance spectroscopy  
°C degrees Celcius 
13
C Carbon-13 
UV Ultraviolet 
nm  nanometers 
m/z mass-to-charge  
ESI electrospray ionization source 
APCI atmospheric pressure chemical ionization source 
APPI atmospheric pressure photo-ionization  
MRM multiple reaction monitoring  
LC/MS Liquid Chromatography Mass Spectrometry 
mL/min milliliters per minute  
ACN Acetonitrile 
MEOH Methanol 
cm  centimeters 
mm millimeters 
µm micrometers 
HPLC High Performance Liquid Chromatography 
pH  potential of hydrogen 
Ig  immunoglobulins 
HRP horseradish peroxidase  
ALP alkaline phosphatase 
TMB tetra-methylbenzidine 
DAB 3, 3’-diaminobenzidine  
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Acronym Full Description 
ABTS 2,2’-aziro-bis (3-ethylbenzthiazoline-6-sulfonic acid)  
PNPP p-nitrophenyl phosphate  
GXP  Good Practice where X can be Laboratory or Manufacturing 
FITC fluorescein isothiocynate 
PE phycoerythrin 
K2EDTA Dipotassium ethylenediaminetetraacetic acid 
g/mol grams per mole 
EU European Union 
ODS Oxide dispersion strengthened alloys 
DISA Disabled Infectious Single Animal  
OIE World Organization for Animal Health  
BTV Bluetongue Virus 
PBS phosphate buffered saline  
FBS Fetal Bovine Serum 
CD4 cluster of differentiation 4 
  
 
